/Dr. Lena Jonsson
Monoclonal antibodies and antibody drug conjugates revolutionize targeted therapies
Monoclonal antibodies and antibody drug conjugates revolutionize targeted therapies
6 Jun 2024

Join Dr. Lena Jonsson, Product Strategy Manager at Cytiva, as she explores the revolutionary impact of monoclonal antibodies (mAbs) in the field of healthcare.

In this video, Dr. Jonsson discusses how mAbs have advanced targeted treatments, allowing for more precise and effective therapy options. She highlights the growing potential of antibody drug conjugates (ADCs) and the importance of maintaining high-quality mAbs to ensure optimal therapeutic outcomes. Dr. Jonsson also provides an in-depth look at the challenges and strategies in scaling up mAb production, emphasizing the role of robust chromatography processes and sophisticated software systems. Discover how Cytiva is at the forefront of innovation, developing products and methodologies that meet the evolving needs of the market and enhance patient care.

Related Scientists

Related Content